-+ 0.00%
-+ 0.00%
-+ 0.00%

ALLOGENE THERAPEUTICS REPORTS FIRST CLINICAL DATA FROM PHASE 1 RESOLUTION STUDY OF ALLO-329 IN AUTOIMMUNE DISEASE

Reuters·11/09/2026 13:03:15